Information:
Fel:
ID
19046
Beskrivning
Effects of a Genistein Concentrated Polysaccharide (GCP) for Prostate Cancer on Active Surveillance.; ODM derived from: https://clinicaltrials.gov/show/NCT00584532
Länk
https://clinicaltrials.gov/show/NCT00584532
Nyckelord
Versioner (1)
- 2016-12-01 2016-12-01 -
Uppladdad den
1 december 2016
DOI
För en begäran logga in.
Licens
Creative Commons BY 4.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
Eligibility Prostate Cancer NCT00584532
Eligibility Prostate Cancer NCT00584532
- StudyEvent: Eligibility
Similar models
Eligibility Prostate Cancer NCT00584532
- StudyEvent: Eligibility
Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
Gender | Prostate carcinoma
Item
participants must be male and have a pathological diagnosis of prostate cancer
boolean
C0079399 (UMLS CUI [1])
C0600139 (UMLS CUI [2])
C0600139 (UMLS CUI [2])
Prostate carcinoma
Item
pathological diagnosis of prostate cancer must be confirmed and on file with cra prior to study entry.
boolean
C0600139 (UMLS CUI [1])
Operative Surgical Procedures | Therapeutic radiology procedure | Hormone Therapy
Item
no treatment (surgery, radiation, or hormones) prior to study entry.
boolean
C0543467 (UMLS CUI [1])
C1522449 (UMLS CUI [2])
C0279025 (UMLS CUI [3])
C1522449 (UMLS CUI [2])
C0279025 (UMLS CUI [3])
Prostate specific antigen measurement
Item
psa between 2.0 and 10.0 ng/ml.
boolean
C0201544 (UMLS CUI [1])
Raised prostate specific antigen | Patient Surveillance Duration
Item
if psa is >10.0, patient must have been on active surveillance for 12 months prior to study initiation.
boolean
C0178415 (UMLS CUI [1])
C0030705 (UMLS CUI [2,1])
C0733511 (UMLS CUI [2,2])
C0449238 (UMLS CUI [2,3])
C0030705 (UMLS CUI [2,1])
C0733511 (UMLS CUI [2,2])
C0449238 (UMLS CUI [2,3])
Allergy to soy | Hypersensitivity Soy product
Item
no known allergy to soy or soy products.
boolean
C4075590 (UMLS CUI [1])
C0020517 (UMLS CUI [2,1])
C1532456 (UMLS CUI [2,2])
C0020517 (UMLS CUI [2,1])
C1532456 (UMLS CUI [2,2])
Genistein Unit per Gram per Day Dietary Supplements
Item
the patient is not currently taking more than 2 grams of genistein a day in nutritional or diet enhancing supplements (otc supplements).
boolean
C0061202 (UMLS CUI [1,1])
C2349072 (UMLS CUI [1,2])
C0242295 (UMLS CUI [1,3])
C2349072 (UMLS CUI [1,2])
C0242295 (UMLS CUI [1,3])
Study Subject Participation Status
Item
participant has not been on any previous gcp clinical trial.
boolean
C2348568 (UMLS CUI [1])
Chemistry normal
Item
normal chemistry values prior to study entry.
boolean
C0854049 (UMLS CUI [1])
Prostate carcinoma
Item
no pathological documentation of prostate cancer.
boolean
C0600139 (UMLS CUI [1])
Therapeutic procedure Prostate carcinoma
Item
prior treatment for prostate cancer.
boolean
C0087111 (UMLS CUI [1,1])
C0600139 (UMLS CUI [1,2])
C0600139 (UMLS CUI [1,2])
Raised prostate specific antigen | Patient Surveillance Duration
Item
psa >10.0 ng/ml but not on active surveillance for 12 months.
boolean
C0178415 (UMLS CUI [1])
C0030705 (UMLS CUI [2,1])
C0733511 (UMLS CUI [2,2])
C0449238 (UMLS CUI [2,3])
C0030705 (UMLS CUI [2,1])
C0733511 (UMLS CUI [2,2])
C0449238 (UMLS CUI [2,3])
Allergy to soy | Hypersensitivity Soy product
Item
allergy to soy or soy products.
boolean
C4075590 (UMLS CUI [1])
C0020517 (UMLS CUI [2,1])
C1532456 (UMLS CUI [2,2])
C0020517 (UMLS CUI [2,1])
C1532456 (UMLS CUI [2,2])
Chemistry abnormal
Item
abnormal chemistry values.
boolean
C0740327 (UMLS CUI [1])